Smith & Nephew (SN) Lifted to Overweight at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Smith & Nephew (LON:SN) to an overweight rating in a report issued on Thursday, January 25th. They currently have GBX 1,411 ($19.49) target price on the stock, up from their prior target price of GBX 1,369 ($18.91).

Other analysts also recently issued reports about the stock. Deutsche Bank reissued a buy rating on shares of Smith & Nephew in a research note on Friday, October 13th. Jefferies Group reaffirmed a buy rating and set a GBX 1,515 ($20.93) price objective on shares of Smith & Nephew in a research note on Thursday, October 12th. Berenberg Bank reaffirmed a hold rating and set a GBX 1,340 ($18.51) price objective on shares of Smith & Nephew in a research note on Friday, November 3rd. Finally, Citigroup reaffirmed a sell rating and set a GBX 1,160 ($16.03) price objective on shares of Smith & Nephew in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. Smith & Nephew has an average rating of Hold and a consensus target price of GBX 1,322.50 ($18.27).

Smith & Nephew (LON:SN) traded up GBX 23 ($0.32) during midday trading on Thursday, hitting GBX 1,250 ($17.27). 2,532,748 shares of the stock were exchanged, compared to its average volume of 2,840,000. Smith & Nephew has a 52 week low of GBX 1,173 ($16.21) and a 52 week high of GBX 1,442 ($19.92). The company has a market cap of $10,940.00 and a P/E ratio of 1,984.13.

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 9th. Shareholders of record on Thursday, April 5th will be issued a $0.23 dividend. This represents a yield of 1.34%. The ex-dividend date of this dividend is Thursday, April 5th. This is a boost from Smith & Nephew’s previous dividend of $0.12.

In other Smith & Nephew news, insider Angie Risley acquired 1,601 shares of the business’s stock in a transaction on Friday, February 9th. The shares were acquired at an average price of GBX 1,249 ($17.26) per share, for a total transaction of £19,996.49 ($27,627.09).

TRADEMARK VIOLATION NOTICE: “Smith & Nephew (SN) Lifted to Overweight at JPMorgan Chase & Co.” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/12/smith-nephew-sn-upgraded-by-jpmorgan-chase-co-to-overweight-updated-updated.html.

Smith & Nephew Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply